Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 18/20 | 0.73 |
| ▸ | TACR3 | P29371 | 17/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.73 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5931065 | 0.93 | TACR3 (0.70) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL6853646 | 0.86 | TACR2 (0.77) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL6902393 | 0.83 | TACR2 (0.80) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5908766 | 0.83 | TACR2 (0.80) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5908764 | 0.83 | TACR2 (0.71) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL7169184 | 0.83 | TACR2 (0.71) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5909035 | 0.80 | TACR2 (0.75) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL6848770 | 0.80 | TACR2 (0.75) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL27563368 | 0.80 | TACR2 (0.74) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5908978 | 0.77 | TACR2 (0.69) | TACR2TACR3OPRM1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235026-A1 | Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2006-10-19 | — | — | US | disclosed |
| US-20040077658-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2004-04-22 | — | — | US | disclosed |
| EP-1334088-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002038548-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235026-A1 | Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | CNR1, HRH4, HRH3 | TACR2 7/4885TACR3 26/4885OPRM1 150/4885 |
| US-20040077658-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | HRH4, HRH2, HRH3 | TACR2 17/4885TACR3 99/4885OPRM1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.